MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

Key findings reported in the study include: MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) s ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (St ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants David Saxon - Needham & Company James Beers - William Blair Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2024 Earnings Res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 80-0625749 (State or other jurisdiction of ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Tom Stephan - Stifel David Saxon - Needham & Company Margaret Kaczor - William Blair Operator Ladies and gentlemen, thank you for standing by and welcome to the ...

Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance MENLO PARK, Calif., March 7, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended Decem ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Margaret Kaczor - William Blair Kallum Titchmarsh - Morgan Stanley Thomas Stephan - Stifel Operator Ladies and gentlemen, thank you for standing by. Welcome to the Sight Sciences' Third Q ...